ClinicalTrials.Veeva

Menu

Dose Escalation Upper Limb Rehabilitation in Stroke

H

Hasselt University

Status

Completed

Conditions

Stroke

Treatments

Other: upper limb rehabilitation

Study type

Interventional

Funder types

Other

Identifiers

NCT04973553
DOMINO-001

Details and patient eligibility

About

A phase 1, single-ascending dose clinical trial will be conducted. This study will be designed to test increasing doses of multimodal exercise in successive cohorts of six participants (cumulative 3 + 3 design)[22] (Figure 1).

Maximum dose is reached when two or more participants experience DLT. DLT, dose-limiting tolerance.

The 'dose' will be defined as the ability to reach a fixed maximal level of exercise (type, duration (including session length) in the first two weeks post-stroke without experiencing dose-limiting tolerance (DLT). DLT thresholds will be based on failure to completeshould be less than 80% of prescribed 3-day rehabilitation dose due to pain, rate of perceived exertion, fatigue, or effort required.

Rehabilitation and measurement sessions will be held at either at the Stroke or Geriatric Units at Campus Sint-Jan, Genk or at the rehabilitation unit at Sint-Barbara, Lanaken and Cliniques Saint-Luc with medical services on site. All participants will be monitored for fatigue and pain pre, during and at post-intervention daily. The researchers (PI of project [Dr Peter Hallet, ZOL] Postdoctoral Researcher [Dr Lisa Tedesco Triccas, UHasselt] and PhD/Masters Students [UHasselt) will conduct the clinical tests and will conduct the rehabilitation program.

Enrollment

18 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. a first-ever unilateral, diagnosed stroke by a neurologist as defined by the World Health Organisation,
  2. been admitted to the acute hospital for rehabilitation,
  3. UL hemiparesis or hemiplegia with a ≥ trace of muscle contraction (≥grade 1 at wrist extensors measured by the MRC Scale and severely motor affected by score of 2 or 3 on item number 5 on the NIH Stroke Scale (NIHSS),
  4. the age of > 18 years and (e) the ability to provide informed consent.

Exclusion criteria

  1. other neurological impairments that could interfere with the protocol such as multiple sclerosis and Parkinson's
  2. serious communication, cognitive and language deficits which might hamper the assessment (score of >1 on the command item of the NIHSS).

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

18 participants in 1 patient group

participants with acute stroke
Experimental group
Description:
(a) a first-ever unilateral, diagnosed stroke by a neurologist as defined by the World Health Organisation, (b) been admitted to the acute hospital for rehabilitation, (c) Upper limb hemiparesis or hemiplegia with a trace of muscle contraction:≥grade 1 at shoulder (abductors or elevators) or wrist/finger extensors measured by the MRC Scale and a score of \<61 on the Motricity Index and severely motor affected by score of 2 or 3 on item number 5 on the NIH Stroke Scale (NIHSS)\[24\], (d) the age of \> 18 years and (e) the ability to provide informed consent.
Treatment:
Other: upper limb rehabilitation

Trial contacts and locations

1

Loading...

Central trial contact

Lisa Tabone, dr.; Peter Feys, prof. dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems